Monographie - Ceftolozane / tazobactam - Stabilis 4.0

Última actualização :
19/11/2024

antibiótico

Ceftolozane / tazobactam

injetável

Estabilidade em soluções simples

Estabilidade em misturas

Factores que afectam a sua estabilidade

Compatibilidade

Método de administração

Bibliografía

pdf

estrutura química

Nomes comerciais nos diversos países

Nomes comerciais nos diversos países

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Zepilen	Espanha
Zerbaxa	Alemanha, Argentina, Chilli, Equator, Espanha, Estados Unidos de América, França, Gran-bretanha, México, Peru, Romènia, Suicia

Bibliografía

injetável

Bibliografía : Ceftolozane / tazobactam

	tipo	publicação
3520	Laboratório	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laboratório	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratório	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratório	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3803	Laboratório	Ceftolozane / tazobactam (Zerbaxa®) - Summary of Product Characteristics Laboratoires Merck Sharp & Dohme Chibret 2020
3827	poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3984	jornal	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
4055	jornal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	jornal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4378	jornal	Harmanjeet H, Jani H, Zaidi S.T.R, Wanandy T, Castelino R.L, Sud K, Peterson G.M, Patel R.P. Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Perit Dial Int 2020 ; 40, 5: 470-476.
4434	jornal	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	jornal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4634	jornal	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4645	jornal	Jamieson C, Drummond F, Hill T, Ozolina L, Gilchrist M, Seaton R.A, Santillo M, Wilkinson A-S, Allwood M.C. Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist 2021
4801	jornal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales